Docetaxel FDA approval date

The FDA approved Docetaxel (Brand of drug is based on institutional procurement) on 14 May 1996.

FDA approval date
14 May 1996

Drug identity checked against registry records

Also recorded as Brand of drug is based on institutional procurement; Docecad; Taxotere; Taxotere®

Included trials

TrialSponsorPhaseStatusPrimary completion
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerNCT06463665Genelux CorporationPhase 2Recruiting2027-02Estimated
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerNCT01630733Achieve Life SciencesPhase 3Completed2016-11-17Actual
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094CADLPhase 3Recruiting2031-10-22Estimated
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCNCT06908304Maia BiotechnologyPhase 3Recruiting2027-07-31Estimated
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381Jazz PharmaceuticalsPhase 2Recruiting2027-12-29Estimated
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor TherapyNCT06745908IBRXPhase 3Recruiting2028-09Estimated
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentNCT04256707KPTIPhase 1, Phase 2Completed2024-07-31Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
1996-05-14DayDocetaxelFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA020449", "applicant_as_listed_by_fda": "SANOFI AVENTIS US", "brand_names": ["TAXOTERE"], "active_ingredients": ["DOCETAXEL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19960514", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026